Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label crossover Phase 2 PK study of IV DHE 45 vs inhaled MAP0004 in smoking and non-smoking adults
2009-016732-12Phase 2Terminated
- Sponsor
- MAP Pharmaceuticals, Inc.
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dihydroergotamine in migraine (2 arms), sponsored by MAP Pharmaceuticals, Inc. Primary endpoint: Plasma levels of DHE and 8'-OH DHE. Started Mar 2010; status: terminated.
02
Drugs
dihydroergotamine
03
Conditions
migraine
Beyond the preview
Go deeper on 2009-016732-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016732-12.